Enhancing PD-1 Blockade in Solid Tumors

Cancer Discov. 2016 Aug;6(8):OF2. doi: 10.1158/2159-8290.CD-NB2016-086. Epub 2016 Jul 1.

Abstract

A phase I study indicates that the combination of utomilumab, an investigational antibody that binds CD137, plus pembrolizumab is safe and well tolerated, yielding sustained responses in patients with various solid cancers.

Publication types

  • Congress

MeSH terms

  • Antibodies, Monoclonal / pharmacology
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / pharmacology
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Clinical Trials, Phase I as Topic
  • Humans
  • Neoplasms / drug therapy*
  • Programmed Cell Death 1 Receptor / antagonists & inhibitors
  • Survival Analysis
  • Treatment Outcome
  • Tumor Necrosis Factor Receptor Superfamily, Member 9 / antagonists & inhibitors*

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor
  • Tumor Necrosis Factor Receptor Superfamily, Member 9
  • pembrolizumab